Management of metastatic phaeochromocytoma and paraganglioma: Use of iodine-131-meta-iodobenzylguanidine therapy in a tertiary referral centre

QJM: An International Journal of Medicine

Volumn 108, Issue 5, 2015, Pages 361-368

  Rutherford, M A ^a   Rankin, A J ^a   Yates, T M ^a   Mark, P B ^b   Perry, C G ^a   Reed, N S ^c   Freel, E M ^a,b  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; IODINE 131; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; HYPOTHYROIDISM; INCIDENCE; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NAUSEA AND VOMITING; OVARY INSUFFICIENCY; PARAGANGLIOMA; PATIENT SAFETY; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RADIATION EXPOSURE; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; TREATMENT OUTCOME; TREATMENT RESPONSE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; DISEASE MANAGEMENT; GENETIC SCREENING; SECONDARY; SECRETION (PROCESS); YOUNG ADULT;

3-IODOBENZYLGUANIDINE; ADOLESCENT; ADRENAL GLAND NEOPLASMS; ADULT; AGED; DISEASE MANAGEMENT; FEMALE; GENETIC TESTING; HUMANS; MALE; MIDDLE AGED; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84954198671     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcu208     Document Type: Article

References (25)

1. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983;58;802-4.
2. Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc 1981; 56:354-60.
3. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346;1459-66.
4. Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Perez L, King EE, et al. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA 2010; 304:2611-9.
5. Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-Garcia LJ, Leton R, et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011; 43:663-7.
6. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011; 96:717-25.
7. Strosberg JR. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol 2013; 40:120-33.
8. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004; 11:423-36.
9. Chen H, Sipperl RS, O'Dorisio MS, Vinik AI, Lloyd R, Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: phaeochromocytoma, paraganglioma and medullary thyroid cancer. Pancreas 2010;39;775-83.
10. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:1915-42.
11. Lehnert H, Mundschenk J, Hahn K. Malignant pheochromocytoma. Front Horm Res 2004; 31:155-62.
12. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergic neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980; 21:349-53.
13. Harari A, Inabnet WB III Malignant pheochromocytoma: a review. Am J Surg 2011; 201:700-8.
14. Hescot S, Leboulleux S, Amar L, Vezzosi D, Borget I, Bournaud-Salinas C, et al. One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. J Clin Endocrinol Metab 2013; 98:4006-12.
15. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003; 134:956-62.
16. Sisson J, Shapiro B, Beierwaltes WH, Nakajo M, Glowniak J, Mangner T, et al. Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans Assoc Am Physicians 1983; 96:209.
17. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol 2001; 55:47-60.
18. Hartley A, Spooner D, Brunt AM. Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands. Clin Oncol UK 2001; 13:361-6.
19. Gedik GK, Hoefnagel CA, Bais E, Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008; 35:725-33.
20. Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20;648-58.
21. van Hulsteijn LT, Niemeijer ND, Dekkers OM, Corssmit EPM. 131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma:systematic review and meta-analysis. Clin Endocrinol 2014; 80:487-501.
22. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009; 27:4162-8.
23. Sze WWC, Grossman A, Goddard I, Amendra D, Shieh SCC, Plowman PN, et al. Sequelae and survivorship in patients treated with 131I-MIBG therapy. Br J Cancer 2013;109;565-75.
24. Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, Fitzgerald PA. High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003; 98:239-48.
25. Lam MG, Lips CJ, Jager PL, Dullaart RP, Lentjes EG, van Rijk PP, et al. Repeated [131I]metaiodobenzylguanidine therapy in two patients with malignant pheochromocytoma. J Clin Endocrinol Metab 2005; 90:5888-95.